Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca has entered into an exclusive global license agreement with LaNova Medicines for LM-305, a potentially first-in-class antibody-drug conjugate…
AstraZeneca has licensed a preclinical GPRC5D-targeting antibody-drug conjugate from Shanghai-based LaNova Medicines in a deal worth up to $600 million. AZ…
Sino Biopharmaceutical to acquire LaNova Medicines for up to ~$950.9M; LaNova's AstraZeneca LM-305 and Merck LM-299 licenses remain intact.
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
AstraZeneca received an exclusive global license to research, develop and commercialize LM-305, a preclinical GPRC5D-targeting ADC. LaNova received up to $55M in upfront/near-term payments plus up to $545M in development/commercial milestones, with tiered royalties on global net sales. Following the license, AstraZeneca renamed the asset AZD0305 and advanced it from preclinical into an AstraZeneca-sponsored modular Phase I/II dose-escalation study in relapsed/refractory multiple myeloma (NCT06106945; study start December 2023), with early dose-escalation data presented at ASH 2024 — validating the deal thesis of in-licensing a preclinical GPRC5D ADC for clinical advancement. (LaNova's own earlier LM-305 trial, NCT05647512, was withdrawn in November 2023 with no enrollment, superseded by AstraZeneca's program.) LaNova Medicines is separately being acquired by Sino Biopharmaceutical (announced July 2025, up to ~$950.9M); the AstraZeneca LM-305 license remains intact.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / LaNova Medicines Ltd. (this deal) | 2023 | $600M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Hematology deals